Corbus Pharmaceuticals Holdings Inc at Goldman Sachs Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Matt Hart - Goldman Sachs - Analyst : Of course. Let's just jump into kind have to two [disting] exciting programs. I'll start off on the oncology side, and then we'll pivot over to metabolic diseases. Starting with the Nectin-4 ADC program. Can you talk a little bit? You recently had some data at ASCO. Can you talk a little bit about the construct there the DAR of two? How that improves the safety profile and tolerability and how that fits within the competitive landscape.

Question: Matt Hart - Goldman Sachs - Analyst : That makes a lot of sense? And then you recently had some data at ASCO with your partner can you -- across multiple tumor types. Can you talk a little bit and give us a summary of what you saw in that latest cut of data that was presented at ASCO. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JUNE 12, 2024 / 6:40PM, CRBP.OQ - Corbus Pharmaceuticals Holdings Inc at Goldman Sachs Global Healthcare Conference

Question: Matt Hart - Goldman Sachs - Analyst : That's great. And you to see validation growth in the early data, but then reinforced that cytotoxicity added ASCO. And then you'll have data from the US study early next year. Can you give us a setup in terms of anticipated patient profile, characteristics of patients? And then how should we think about what constitutes a compelling response profile in the anticipated?

Question: Matt Hart - Goldman Sachs - Analyst : How many patients (technical difficulty) at that time.

Question: Matt Hart - Goldman Sachs - Analyst : Right. (inaudible) of a minute. [Like I said]. All right. Shifting gears away from Nectin-4 to obesity and the CB1 inverse agonist, that's re-emerge as a target of interest. Can you introduce the mechanism here and discuss a little bit the differentiation of the second-generation programs versus the first generation (technical difficulty) agonist?

Question: Matt Hart - Goldman Sachs - Analyst : And you mentioned that this in second generation of CB1 coming into focus, particularly with the Inversago acquisition last year in August, and that these are two cousin or distant cousin molecules. Can you talk about what has been demonstrated clinically with the Inversago now Novel molecule both? I think [Inversago] some initial data at their R&D day and then subsequently, they've had some commentary at recent conferences. Can you just comment on what they've shared and how that sets expectations are thinking through for your program.

Question: Matt Hart - Goldman Sachs - Analyst : And so this teased this high teens efficacy on the safety side, certainly encouraging. That's here (technical difficulty) turning to dose higher. So that's great. Can you talk a little bit about, what you could discuss a little bit, what they're suggesting. How does what the Novo data look like later this year, inform your clinical strategy and how you guys are thinking about?

Question: Matt Hart - Goldman Sachs - Analyst : And you touched on this a little bit, but can you elaborate a little bit more on how the mechanism and the molecule fit into the clinical and ultimately commercial landscape. I mean, you've touched a little bit on patients that are in -- so aren't that sensitive to integrate therapies and or hypersensitive? I think we're starting to see that there's more dropout rates and compliance rates are more challenging or higher than people anticipated, given the therapeutic benefit of this program. So can you touch a little bit about how you think this molecule plays a role in the evolving landscape from a commercial perspective. And then the studies that we need to be done to complement the initial weight loss studies, get the full payer by and support and recognizing that this could [potentially be achieve].

Question: Matt Hart - Goldman Sachs - Analyst : And perhaps you can in the maintenance of offices, perhaps you can titrate down the dose over the doses and I mean it has much exposure.

Question: Matt Hart - Goldman Sachs - Analyst : Rapping up here. You did a financing this year. The company is well capitalized to unlock multiple milestones to continue to execute across both programs. Can you touch on it as we close here, the milestones for both programs, cash runway guidance and then anything else you want to cover in closing?

Question: Matt Hart - Goldman Sachs - Analyst : Well, thank you very much for your time. Appreciate you coming down to Florida. Hopefully you can make it back on your flight tomorrow, given the weather, but it's been a pleasure to have you. Thanks, Yuval.